Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Short Review: Lipid-Lowering Therapies, Where are we Heading?
*Corresponding Author:
Copyright: © 2021 . This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
To read the full article Peer-reviewed Article PDF 
Abstract
With the presently available drugs, low-density lipoprotein cholesterol (LDL-c) can be reduced to current guideline recommendations. Despite very low LDL-c, patients continue to experience atherosclerotic cardiovascular disease (ASCVD) complications. To address this “residual” risk, new potentially manageable lipoproteins have become the next therapeutic targets, i.e. Lp(a) and triglyceride rich lipoproteins (TRL).
